1. Harmony Biosciences will participate in a chat at the Cantor Global Healthcare Conference. 2. The event occurs on September 4, 2025, at 2:10 p.m. ET. 3. A webcast will be available on their investor page post-event. 4. Harmony specializes in therapies for patients with rare neurological diseases. 5. The company is committed to addressing unmet medical needs for these conditions.
Participation in a significant healthcare conference can enhance visibility and investor interest. Previous examples show conferences positively influenced stock prices of biotech firms.
The article highlights a strategic engagement that may improve investor sentiment and awareness of HRMY's developments.
The event will foster ongoing engagement with investors, which can lead to sustained interest over time. Historical data indicates that companies enhancing visibility at conferences experience prolonged positive stock movements.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 4, 2025, at 2:10 p.m. ET.
A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250821677714/en/
Investor Contact:
Matthew Beck
astr partners
917-415-1750
matthew.beck@astrpartners.com
Media Contact:
Cate McCanless
Harmony Biosciences
202-641-6086
cmccanless@harmonybiosciences.com